Using this data we defined the set of 56.9% differentially expressed genes as positively regulated by KDM3A activity (down in the CRL-2505 prostate cancer line with shRNA knockdown of KDM3A), and 43.1% of differentially expressed genes as negatively regulated by KDM3A activity. This evidence concerns the gene KDM3A and prostate carcinoma.